AU2021391581A1 - Deuterated or partially deuterated n,n-dimethyltryptamine compounds - Google Patents
Deuterated or partially deuterated n,n-dimethyltryptamine compounds Download PDFInfo
- Publication number
- AU2021391581A1 AU2021391581A1 AU2021391581A AU2021391581A AU2021391581A1 AU 2021391581 A1 AU2021391581 A1 AU 2021391581A1 AU 2021391581 A AU2021391581 A AU 2021391581A AU 2021391581 A AU2021391581 A AU 2021391581A AU 2021391581 A1 AU2021391581 A1 AU 2021391581A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- compounds
- composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2018955.1 | 2020-12-01 | ||
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| US17/108,938 | 2020-12-01 | ||
| US17/208,583 | 2021-03-22 | ||
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| GB2103981.3 | 2021-03-22 | ||
| AUPCT/EP2021/060750 | 2021-04-23 | ||
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
| GB2106881.2A GB2595776B (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| CA3118556A CA3118556A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| GB2106881.2 | 2021-05-13 | ||
| PCT/EP2021/062794 WO2021244831A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| US17/320,155 | 2021-05-13 | ||
| US17/320,155 US12042564B2 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| CA3118556 | 2021-05-13 | ||
| AUPCT/EP2021/062794 | 2021-05-13 | ||
| PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021391581A1 true AU2021391581A1 (en) | 2023-07-06 |
Family
ID=88294961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021391581A Pending AU2021391581A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4031529B1 (https=) |
| JP (1) | JP7834754B2 (https=) |
| CN (1) | CN116761599B (https=) |
| AU (1) | AU2021391581A1 (https=) |
| CA (1) | CA3203020A1 (https=) |
| IL (1) | IL303288A (https=) |
| TW (1) | TWI891942B (https=) |
| WO (1) | WO2022117359A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CA3152752A1 (en) | 2019-10-01 | 2021-04-08 | Thomas Henley | Genetic engineering of fungi to modulate tryptamine expression |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| KR20220137081A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| EP4433049A1 (en) * | 2021-11-18 | 2024-09-25 | Cybin UK Ltd | Injectable and inhalable formulations |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| CN118984868A (zh) | 2021-12-31 | 2024-11-19 | 恩派瑞安神经科学公司 | 用于产生精神药物生物碱的遗传修饰的生物体 |
| EP4463440A1 (en) * | 2022-01-14 | 2024-11-20 | Cybin IRL Limited | Tryptamine compositions and methods |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| AU2023361184A1 (en) | 2022-10-13 | 2025-04-24 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
| WO2024108195A1 (en) | 2022-11-17 | 2024-05-23 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| CN121038789A (zh) | 2023-01-23 | 2025-11-28 | 赛本英国有限公司 | 通过肠胃外施用单一有效肠胃外剂量的短效致幻剂治疗精神或神经障碍 |
| CN121194779A (zh) | 2023-03-31 | 2025-12-23 | 赛本英国有限公司 | 包含单胺抗抑郁剂和短效致幻剂的组合 |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2337507A1 (en) * | 1998-07-16 | 2000-01-27 | Massachusetts Institute Of Technology | Composition for treatment of stress |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220137081A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| MX2022014900A (es) * | 2020-06-02 | 2023-03-27 | Small Pharma Ltd | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11000534B1 (en) * | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-11-18 EP EP21815486.2A patent/EP4031529B1/en active Active
- 2021-11-18 AU AU2021391581A patent/AU2021391581A1/en active Pending
- 2021-11-18 CA CA3203020A patent/CA3203020A1/en active Pending
- 2021-11-18 WO PCT/EP2021/082227 patent/WO2022117359A1/en not_active Ceased
- 2021-11-18 IL IL303288A patent/IL303288A/en unknown
- 2021-11-18 TW TW110143066A patent/TWI891942B/zh active
- 2021-11-18 JP JP2023533243A patent/JP7834754B2/ja active Active
- 2021-11-18 EP EP23198784.3A patent/EP4275753B1/en active Active
- 2021-11-18 CN CN202180090269.1A patent/CN116761599B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN116761599A (zh) | 2023-09-15 |
| WO2022117359A1 (en) | 2022-06-09 |
| CA3203020A1 (en) | 2022-06-09 |
| IL303288A (en) | 2023-07-01 |
| EP4275753B1 (en) | 2026-03-18 |
| CN116761599B (zh) | 2025-05-30 |
| EP4031529A1 (en) | 2022-07-27 |
| JP2023551058A (ja) | 2023-12-06 |
| EP4275753A2 (en) | 2023-11-15 |
| EP4031529C0 (en) | 2023-09-27 |
| EP4275753A3 (en) | 2023-12-27 |
| JP7834754B2 (ja) | 2026-03-24 |
| EP4031529B1 (en) | 2023-09-27 |
| TW202237565A (zh) | 2022-10-01 |
| TWI891942B (zh) | 2025-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4031529B1 (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| US12251371B2 (en) | Deuterated or partially deuterated N,N-dimethyltryptamine compounds | |
| US11773062B2 (en) | Deuterated compounds | |
| EP3873883B1 (en) | Method of synthesis | |
| US12521370B2 (en) | Inhalable formulations | |
| EP4255421A1 (en) | Inhalable formulations | |
| US20220169606A1 (en) | Compositions and compounds for bioanalysis | |
| HK40103232A (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| HK40078818B (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| HK40078818A (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| GB2605144A (en) | Deuterated compounds | |
| HK40060666A (en) | Method of synthesis | |
| HK40060666B (en) | Method of synthesis | |
| HK40056359B (en) | Compounds | |
| HK40056359A (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: CYBIN UK LTD Free format text: FORMER NAME(S): SMALL PHARMA LTD |